- Home
- ESAB vs ROIV Comparison
ESAB vs ROIV Comparison
Compare ESAB & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ESAB | ROIV |
|---|---|---|
| Founded | 1904 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 14.1B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ESAB | ROIV |
|---|---|---|
| Price | $112.54 | $22.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $140.38 | $24.31 |
| AVG Volume (30 Days) | 465.1K | ★ 8.3M |
| Earning Date | 02-19-2026 | 02-09-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.95 | N/A |
| Revenue | ★ $2,792,325,000.00 | $20,329,000.00 |
| Revenue This Year | $3.25 | N/A |
| Revenue Next Year | $8.37 | $741.42 |
| P/E Ratio | $25.18 | ★ N/A |
| Revenue Growth | ★ 1.19 | N/A |
| 52 Week Low | $100.17 | $8.73 |
| 52 Week High | $135.84 | $23.47 |
Technical Indicators
Market Signals| Indicator | ESAB | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 47.96 | 56.28 |
| Support Level | $111.25 | $21.36 |
| Resistance Level | $114.80 | $22.72 |
| Average True Range (ATR) | 2.42 | 0.72 |
| MACD | -0.17 | -0.13 |
| Stochastic Oscillator | 17.19 | 32.69 |
Price Performance
Historical ComparisonAbout ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.